Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety
- PMID: 16514059
- DOI: 10.1182/blood-2006-01-0054
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety
Abstract
Ventricular tachyarrhythmias may occur during intravenous arsenic trioxide (As2O3). This has not happened during oral As2O3. Sixteen patients were studied by electrocardiography and 24-hour Holter monitoring at baseline, during and after oral As2O3 (As2O3-ON, As2O3-OFF). QT and corrected QT (QTc) were significantly longer during As2O3-ON than in As2O3-OFF, but QT and QTc dispersions were comparable. The patients' 24-hour heart rates were higher during As2O3-ON than in As2O3-OFF. QTc intervals at each hour were longer during As2O3-ON than in As2O3-OFF. However, QTc prolongation of more than 30 milliseconds only occurred at one time point (2 hours) after oral As2O3, resulting in QTc of more than 500 milliseconds in 3 of 16 patients, all within 4 hours of oral As2O3. Although the standard deviation of normal RR interval was lower during As2O3-ON, ratios of low frequency to high frequency power for As2O3-ON and As2O3-OFF were comparable. No ventricular proarrhythmias were observed. These observations, due to the lower peak plasma arsenic reached during oral As2O3, may explain the relative cardiac safety of oral As2O3.
Similar articles
-
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.J Clin Oncol. 2003 Oct 1;21(19):3609-15. doi: 10.1200/JCO.2003.10.009. J Clin Oncol. 2003. PMID: 14512391
-
Arsenic trioxide: safety issues and their management.Acta Pharmacol Sin. 2008 Mar;29(3):296-304. doi: 10.1111/j.1745-7254.2008.00771.x. Acta Pharmacol Sin. 2008. PMID: 18298894 Review.
-
Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.Int J Cardiol. 2020 May 1;306:163-167. doi: 10.1016/j.ijcard.2019.11.099. Epub 2019 Nov 18. Int J Cardiol. 2020. PMID: 31761398
-
[Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].Zhonghua Xue Ye Xue Za Zhi. 1997 May;18(5):250-3. Zhonghua Xue Ye Xue Za Zhi. 1997. PMID: 15622757 Clinical Trial. Chinese.
-
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.Leuk Lymphoma. 2000 Jul;38(3-4):283-93. doi: 10.3109/10428190009087019. Leuk Lymphoma. 2000. PMID: 10830735 Review.
Cited by
-
Pharmacokinetic Properties of Arsenic Species after Intravenous and Intragastrical Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS.Molecules. 2019 Jan 10;24(2):241. doi: 10.3390/molecules24020241. Molecules. 2019. PMID: 30634677 Free PMC article.
-
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction.Front Med. 2011 Mar;5(1):45-52. doi: 10.1007/s11684-011-0117-y. Epub 2011 Mar 17. Front Med. 2011. PMID: 21681674 Review.
-
In silico mechanisms of arsenic trioxide-induced cardiotoxicity.Front Physiol. 2022 Dec 15;13:1004605. doi: 10.3389/fphys.2022.1004605. eCollection 2022. Front Physiol. 2022. PMID: 36589437 Free PMC article.
-
Ascorbic Acid Sensitizes Colorectal Carcinoma to the Cytotoxicity of Arsenic Trioxide via Promoting Reactive Oxygen Species-Dependent Apoptosis and Pyroptosis.Front Pharmacol. 2020 Feb 21;11:123. doi: 10.3389/fphar.2020.00123. eCollection 2020. Front Pharmacol. 2020. PMID: 32153415 Free PMC article.
-
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.Clin Cancer Res. 2014 Oct 1;20(19):4985-93. doi: 10.1158/1078-0432.CCR-13-2725. Clin Cancer Res. 2014. PMID: 25274377 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous